Advances In Precision Medicine Will Transform Oncology Markets
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 11 Analysts
Published
06 Aug 25
Updated
16 Aug 25
AnalystHighTarget's Fair Value
US$56.00
71.9% undervalued intrinsic discount16 Aug
US$15.74
1Y
-21.0%7D
26.1%